Macrophage inflammatory protein-1α (MIP-1α) enhances a receptor activator of nuclear factor κB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/ Akt pathways

Molecular and Cellular Biochemistry

Volumn 304, Issue 1-2, 2007, Pages 53-60

  Tsubaki, Masanobu ^a   Kato, Chisato ^a   Manno, Miyuki ^a   Ogaki, Mitsuhiko ^a   Satou, Takao ^b   Itoh, Tatsuki ^b   Kusunoki, Takashi ^b   Tanimori, Yoshihiro ^c   Fujiwara, Kimiko ^c   Matsuoka, Hiroshi ^d   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KINDAI UNIVERSITY HOSPITAL   (Japan)

^d KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

Author keywords

Bone marrow stromal cells; Macrophage inflammatory protein 1 ; MAPK; MIP 1 ; Myeloma; Osteoblast; PI3K Akt; RANKL; Receptor activator of nuclear factor B ligand

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; BONE ATROPHY; BONE DESTRUCTION; BONE MARROW; BONE PAIN; CELL ACTIVATION; CELL DIFFERENTIATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG TARGETING; ENZYME PHOSPHORYLATION; FRACTURE; GENE EXPRESSION; MOUSE; MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PROTEIN EXPRESSION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; STEM CELL; STROMA CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BONE MARROW CELLS; BUTADIENES; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINE CCL3; CHROMONES; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; IMIDAZOLES; MICE; MORPHOLINES; NITRILES; ONCOGENE PROTEIN V-AKT; OSTEOBLASTS; OSTEOCLASTS; PHOSPHORYLATION; PYRIDINES; RANK LIGAND; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 34648814031     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-007-9485-7     Document Type: Article

References (21)

1. Takahashi N, Udagawa N, Suda T (1999) A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256:449-455
2. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T (1999) Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand. Bone 25:517-523
3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
4. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581-11586
5. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527-3533
6. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijizen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534-3540
7. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100:2195-2202
8. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97:3349-3353
9. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, Suda T, Takahashi N (2002) p38MAPK MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143:3105-3113
10. Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K (2005) Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 328:91-97
11. Miyamoto A, Kunisada T, Hemmi H, Yamane T, Yasuda H, Miyake K, Yamazaki H, Hayashi SI (1998) Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochem Biophys Res Commun 242:703-709
12. Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A (2004) Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 126:686-689
13. Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo JT, Martin TJ, Nagai K, Suda T (2000) Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 141:4711-4719
14. Takeda S, Yoshizawa T, Nagai Y, Yamato H, Fukumoto S, Sekine K, Kato S, Matsumoto T, Fujita T (1999) Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: Studies using VDR knockout mice. Endocrinology 140:1005-1008
15. O'Brien CA, Lin SC, Bellido T, Manolagas SC (2000) Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines. J Cell Biochem 79:532-541
16. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC (1999) STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274:19301-19308
17. Fu Q, Jilka RL, Manolagas SC, O'Brien CA (2002) Parathyroid hormone stimulates receptor activator of NF-kappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875
18. Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM, Raisz LG (2000) Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141:2054-2061
19. Kim YH, Kim JM, Kim SN, Kim GS, Baek JH (2003) p44/42 MAPK activation is necessary for receptor activator of nuclear factor-kappaB ligand induction by high extracellular calcium. Biochem Biophys Res Commun 304:729-735
20. Li F, Chung H, Reddy SV, Lu G, Kurihara N, Zhao AZ, Roodman GD (2005) Annexin II stimulates RANKL expression through MAPK. J Bone Miner Res 20:1161-1167
21. Okamatsu Y, Kim D, Battaglino R, Sasaki H, Spate U, Stashenko P (2004) MIP-1 gamma promotes receptor-activator-of-NF-kappaB-ligand-induced osteoclast formation and survival. J Immunol 173:2084-2090